Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CTSO | Common Stock | Options Exercise | $31.8K | +12K | +9.23% | $2.65 | 142K | Feb 6, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CTSO | Stock Option (right to buy) | Options Exercise | $0 | -12K | -100% | $0.00* | 0 | Feb 6, 2023 | Common Stock | 12K | $2.65 | Direct | F2 |
Id | Content |
---|---|
F1 | Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person. |
F2 | The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant. |